Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 3, 2012, Pages 297-304

  Devold, Helene M ^a   Furu, Kari ^a   Skurtveit, Svetlana ^a   Tverdal, Aage ^b   Falch, Jan A ^a   Sogaard, Anne Johanne ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Adherence; Alendronate; Bisphosphonates; Incident users; Norway; Osteoporosis; Socio economy

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; IBANDRONIC ACID; RALOXIFENE;

ADULT; AGED; ARTICLE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; GROUPS BY AGE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NORWAY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIAL STATUS;

ADULT; AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MARITAL STATUS; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORWAY; OSTEOPOROSIS; PROSPECTIVE STUDIES; SEX FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84858279004     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2344     Document Type: Article

References (37)

1. WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and Management of Osteoporosis, Geneva, Switzerland 921, 2003; 1-164.
2. NIH Consensus Development Panel on Osteoporosis Prevention DaT. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-95.
3. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-7.
4. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399-428.
5. Borgstrom F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006; 17: 996-1007.
6. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
7. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52.
8. Johnell O, Jonsson B, Jonsson L, Black D. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21: 305-14.
9. Tosteson AN, Melton LJ, III, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008; 19: 437-47.
10. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003-8.
11. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-61.
12. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013-22.
13. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101, 038 new bisphosphonate users. J Bone Miner Res 2008; 23: 1435-41.
14. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38: 922-8.
15. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008; 19: 811-8.
16. Evans RG, Stoddart GL. Consuming research, producing policy? Am J Public Health 2003; 93: 371-9.
17. Farahmand BY, Persson PG, Michaelsson K, Baron JA, Parker MG, Ljunghall S. Socioeconomic status, marital status and hip fracture risk: a population-based case-control study. Osteoporos Int 2000; 11: 803-8.
18. Navarro MC, Sosa M, Saavedra P, et al. Poverty is a risk factor for osteoporotic fractures. Osteoporos Int 2009; 20: 393-8.
19. Varenna M, Binelli L, Zucchi F, Ghiringhelli D, Gallazzi M, Sinigaglia L. Prevalence of osteoporosis by educational level in a cohort of postmenopausal women. Osteoporos Int 1999; 9: 236-41.
20. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010; 106: 86-94.
21. WHO Collaborating Centre for Drug Statistics Methodology. Guildelines for ATC classification and DDD assignment 2009, Oslo, 2008.
22. nd September 2009].
23. th August 2009].
24. nd September].
25. nd September 2009].
26. Devold HM, Doung GM, Tverdal A, et al. Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. Eur J Clin Pharmacol 2010; 66: 299-306.
27. Strand BH, Kunst A. Childhood socioeconomic status and suicide mortality in early adulthood among Norwegian men and women. A prospective study of Norwegians born between 1955 and 1965 followed for suicide from 1990 to 2001. Soc Sci Med 2006; 63: 2825-34.
28. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-74.
29. Nietert PJ, Tilley BC, Zhao W, et al. Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Med Care 2009; 47: 32-40.
30. Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 2009; 20: 299-307.
31. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007; 120: 251-6.
32. Nielsen DS, Langdahl BL, Sorensen OH, Sorensen HA, Brixen KT. Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study. Scand J Public Health 2010; 38: 502-7.
33. Magnus JH, Joakimsen RM, Berntsen GK, Tollan A, Soogaard AJ. What do Norwegian women and men know about osteoporosis? Osteoporos Int 1996; 6: 32-6.
34. Demeter S, Leslie WD, Lix L, MacWilliam L, Finlayson GS, Reed M. The effect of socioeconomic status on bone density testing in a public health-care system. Osteoporos Int 2007; 18: 153-8.
35. Finkelstein MM. Preventive screening. What factors influence testing? Can Fam Physician 2002; 48: 1494-501.
36. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-60.
37. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008; 24: 1337-44.